BlueSphere Bio to Present at the Next Generation CAR & T Cell Therapies Conference
2023-03-01
细胞疗法临床申请免疫疗法临床研究
BlueSphere Bio to Present at the Next Generation CAR & T Cell Therapies Conference
PITTSBURGH, Pa., March 01, 2023 (GLOBE NEWSWIRE) -- BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for patients with hematologic malignancies and solid tumors, today announced Robert Keefe, Ph.D., Chief Development Officer of BlueSphere Bio, will present an overview of the Company’s anticipated first in human clinical candidate, BSB-1001, and its discovery using the TCXpress™ platform at the Next Generation CAR & T Cell Therapies Conference held in San Diego, CA from February 27 – March 3, 2023.
BSB-1001, targeting the minor histocompatibility antigen-1 (HA-1) and part of BlueSphere’s TCX-101 Program, is the first TCR-based clinical candidate generated using TCXpress and is in development for the treatment of acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL) and myeloid dysplastic syndrome (MDS) in conjunction with allogeneic hematopoietic stem cell transplantation (alloSCT). BlueSphere anticipates filing its first Investigational New Drug Application (IND) for BSB-1001 in 2023.
Presentation details:
Title: A Powerful Platform to Find TCRs to Defined Targets: Applications in Allogeneic Stem Cell Transplantation
Date: Thursday, March 2, 2023
Time: 11:30 a.m. – 12:00 p.m. PST
Location: San Diego Convention Center
For more information about the Next Generation CAR & T Cell Therapies Conference, please refer to the conference website at https://informaconnect.com/car-t/.
About BlueSphere Bio
BlueSphere Bio is the first translational sciences stand-alone company formed by UPMC Enterprises, the innovation, commercialization, and venture capital arm of the Pittsburgh-based health system. The Company was founded upon the unique, advanced TCR discovery platform – TCXpress™, designed to isolate and functionally characterize TCRs with speed and efficiency. This platform can be used in various clinical settings to discover TCRs for use in either TCR-based cell therapy or in antibody-like molecules, such as bi-specific T cell engagers. While the Company’s initial focus is oncology, the platform could be deployed in other therapeutic areas, such as auto-immunity.
BSB-1001, targeting the minor histocompatibility antigen-1 (HA-1) and part of BlueSphere’s TCX-101 Program, is the first TCR-based clinical candidate generated using TCXpress and is in development for the treatment of acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL) and myeloid dysplastic syndrome (MDS) in conjunction with allogeneic hematopoietic stem cell transplantation (alloSCT). BlueSphere anticipates filing its first IND application for BSB-1001 in 2023. In addition, the TCXpress platform has enabled the discovery of several new TCRs reactive against other clinically relevant miHAs, which will become part of the TCX-101 Program as a panel that positions the Company with best-in-class population coverage in these indications.
In addition to TCX-101, BlueSphere is currently identifying a broad panel of TCRs to deploy in its first solid tumor program, which will be announced later this year. Concurrent with its use for shared antigens, BlueSphere is deploying TCXpress™ and NEOXpress™, a proprietary patient-specific neoantigen discovery platform, to develop its TCX-201 Program, which aims to identify TCRs reactive against patient-specific neoantigens. The Company anticipates virtual patient data from multiple solid tumor types this year.
Company Contact
Kim Jaffe
Senior Vice President, Head of Business Development & Strategy
+1- 609-306-7042
kjaffe@bluespherebio.com
Media Contact
Andrew Mielach
LifeSci Communications
+1-646-876-5868
amielach@lifescicomms.com
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。